HBV Clinical Trial
Official title:
To Study the Efficacy of 'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT - A Randomized Control Trial
After fulfillment of the selection criteria, all the patients included in the trial will be administered Tenofovir that will be continued for 3 months and then stopped for 1 month, LFT's, HBV DNA, HBsAg, will be checked weekly during the time period of stopping Tenofovir and thereafter at 4 months patients with ALT >/= 1.5 times ULN will be randomised in 2 groups to administer either Peg INF alpha 2b + Tenofovir (in same dose as before) or Tenofovir alone which will be continued for 48 weeks and the patients with no rise in ALT will be excluded. Patients will be closely monitored during the period of stopping tenofovir post pulse therapy and liver function tests will be performed weekly. Patients will be closely observed for the development of acute hepatitis or decompensation during the 4 - week period of drug withdrawal. Thereafter, CBC, KFT, LFT's, PT-INR, HBsAg (Q), HBeAg and HBV DNA levels will be tested every 3 months. After stopping treatment followup will be done at 24 weeks post stoppage of treatment to look for sustained seroconversion and virological/biochemical response
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05442437 -
Clinical Study of hUC-MSCs Treating Decompensated Liver Cirrhosis With HBV
|
Early Phase 1 | |
| Completed |
NCT04519710 -
Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies
|
N/A | |
| Recruiting |
NCT04562051 -
Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients
|
||
| Recruiting |
NCT04683341 -
Tenofovir Alafenamide in HBV Related Decompensated Liver
|
Phase 4 | |
| Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
| Completed |
NCT02044068 -
Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women
|
N/A | |
| Completed |
NCT03239353 -
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04904835 -
Access HBV Assays - European Union (EU) Clinical Trial Protocol -
|
||
| Terminated |
NCT04059198 -
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
|
Phase 2 | |
| Not yet recruiting |
NCT05293158 -
Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study
|
N/A | |
| Not yet recruiting |
NCT05028322 -
Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen
|
Phase 2 | |
| Completed |
NCT02312531 -
Prevention for Mother-to-infant Transmission of HBV
|
N/A | |
| Not yet recruiting |
NCT01556815 -
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05786859 -
The Efficacy and Safety of Rifaximin Treatment
|
Early Phase 1 | |
| Recruiting |
NCT05951751 -
The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM)
|
N/A | |
| Not yet recruiting |
NCT06307808 -
Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination
|
||
| Completed |
NCT03149627 -
Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
|
||
| Recruiting |
NCT04886336 -
The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.
|
||
| Recruiting |
NCT04568265 -
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
|
Phase 2 | |
| Terminated |
NCT02826018 -
A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
|
Phase 1 |